Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 5/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982044 | 0.83 | SMN1; SMN2 (0.39) | RAB9AMEN1NPC1GAAKMT2A | |
| SCHEMBL9370108 | 0.76 | CYP17A1 (0.42) | CYP17A1ATRNAMPTGSK3BDYRK1A | |
| SCHEMBL17654329 | 0.76 | RAB9A (0.34) | CYP17A1ATRNAMPTRAB9AMEN1 | |
| SCHEMBL6826193 | 0.75 | NAMPT (0.39) | CYP17A1ATRNAMPTGSK3BDYRK1A | |
| SCHEMBL31038470 | 0.73 | NAMPT (0.46) | CYP17A1ATRNAMPTGSK3BDYRK1A | |
| SCHEMBL28022015 | 0.73 | CYP17A1 (0.48) | CYP17A1ATRNAMPTGSK3BDYRK1A | |
| SCHEMBL4093611 | 0.73 | NAMPT (0.46) | CYP17A1ATRNAMPTGSK3BDYRK1A | |
| SCHEMBL30513278 | 0.73 | CYP17A1 (0.48) | CYP17A1ATRNAMPTGSK3BDYRK1A | |
| SCHEMBL5838255 | 0.72 | ATR (0.47) | CYP17A1ATRNAMPTGSK3BDYRK1A | |
| SCHEMBL29394473 | 0.71 | LCK (0.47) | NAMPTGSK3BDYRK1AMETAP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| EP-1803719-A1 | 1,5-DIHETEROCYCLE-1H-TRIAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | PTGS1, PTGER1, TBXA2R | CYP17A1 491/4885ATR 3962/4885NAMPT 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.